Matthew Sirott
Hematology & Oncology · Pleasant Hill, CANPI 1023014461
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,287 of the $2,556 with a category attached, or 89.5%. It is spread thinly across 31 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,103 and has fallen 92.1% since, to $87 in 2023. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 140 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$366
- Amgen$328
- Johnson & Johnson$265
- Pfizer$171
- Novartis$127
- Lilly USA, LLC$126
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,28789%
- Education$26911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 25 | $366 |
| Amgen | 13 | $328 |
| Johnson & Johnson | 31 | $265 |
| Pfizer | 10 | $171 |
| Novartis | 6 | $127 |
| Lilly USA, LLC | 6 | $126 |
| Incyte Corporation | 2 | $118 |
| Gilead | 5 | $117 |
| Seagen Inc. | 5 | $114 |
| AstraZeneca | 4 | $92 |
| Sanofi | 4 | $85 |
| Merck | 4 | $75 |
| Tersera Therapeutics LLC | 2 | $70 |
| Genentech USA, Inc. | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Bristol Myers Squibb | 2 | $54 |
| Elekta, Inc. | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Tesaro, Inc. | 1 | $26 |
| Clovis Oncology, Inc. | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| Novocure Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Mylan Institutional Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Myovant Sciences Inc. | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$2,556 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Pleasant Hill
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.